Terri Lee, Ph.D.
Investment and Operations Team
San Francisco Office
Dr. Terri Lee is responsible for investment identification, due diligence, company formation and business development activities at MPM. Terri has led diligence and supported multiple MPM investments, including Arialys, Photys (Board Observer), and Protego. Currently, Terri serves in strategic operational roles at BioIntervene and at a newly formed, stealth MPM startup company.
Terri received her Ph.D. in Biochemistry and Molecular Biology from the University of California, San Francisco, where her thesis focused on the role of actin nucleators in DNA repair pathways. In addition to academic research, Terri worked on identifying commercial opportunities and company formation at the Gladstone Institutes, including taking on an operations role at a therapeutics company in the neurodegenerative space.
Terri received her B.S. in Pharmacology and Microbiology from the University of California, Santa Barbara.